Tag Archives: TIF News

  Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease pathology and associated (iron load mainly in the case of thalassaemia) co-morbidities, are defined as high-risk individuals, prone to develop more severe complications from SARS-COV-2. Despite the fact that ...

Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells. One of the novel therapies  for thalassaemia that has stood out recently has undoubtedly been the first and only, one-time, groundbreaking gene therapy for transfusion ...

  TIF was excited to participate in the 25th European Hematology Association (EHA) Annual  Virtual Congress, held this year virtually on 11 – 21 June 2020. Dr Androulla Eleftheriou (TIF Executive Director) and Ms Lily Cannon (TIF Operations Manager) have attended the following satellite symposia on 11 June: MDS AND ...

Safe blood saves lives This year, World Blood Donor Day will once again take place in every country of the world on 14 June and TIF will be joining the celebrations! The event serves to thank voluntary, unpaid blood donors for their life-saving gifts of blood and also to raise awareness ...

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of patients with NTDT α- and β-thalassaemia. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety ...

Prevention is the only measure that can drastically reduce the incidencies of severe haemoglobin disorders, such as β-thalassaemia.   It is also what allowed countries like Greece, Italy and Cyprus to go from historically high rates of thalassaemia to a substantial decrease of thalassaemia major cases in the last decades. ...

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassaemia syndromes, when current chelation therapy is inadequate. The new formulation of ...

The 1st webinar for Medical Specialists organised in the context of TIF’s eThalEd online course has just arrived! Dr Antonio Piga, Professor of Paediatrics & Dean of the Medicine School at San Luigi University Hospital of the Turin University, will be the host of this introductory webinar entitled ”Access to New Therapies: Reblozyl”. ...

TIF expresses major concerns over the announcement of the United States to suspend financial support for the World Health Organisation (WHO) until completion of a review of the organisation’s activities related to the COVID-19 pandemic.

On 16 April, TIF and the European Hematology Association (EHA) successfully organised a highly interactive webinar entitled ”Thalassaemia/SCD and COVID-19: Possible risks and a proposal for a patient pathway during the pandemic”, which registered more than 700 participants from all over the world! Experts from Italy & Cyprus, inclufing TIF’s ...